PI3K inhibitor LY294002 corrected dysregulated synaptic protein synthesis, excess AMPA receptor internalization and the increased spine density in Fmr1 knockout neurons, supporting PI3K as a potential therapeutic target for fragile X syndrome (Gross et al., 2010). Here, FMR1 is linked to fragile X syndrome.